Cadila Healthcare or Lupin developing Today News
Lupin developing new drugs to treat cancer, metabolic disorders-
Lupin is developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders. The Novel Drug Discovery and Development (NDDD) is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities in various therapeutic areas like oncology, immunology, and metabolic disorders.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products, and APIs globally.
Cadila Healthcare trades in green on the bourses-
Cadila Healthcare is currently trading at Rs. 351.20, up by 2.00 points or 0.57% from its previous closing of Rs. 349.20 on the BSE.
The scrip opened at Rs. 352.00 and has touched a high and low of Rs. 353.40 and Rs. 349.70 respectively.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 450.95 on 15-Jan-2018 and a 52 week low of Rs. 330.65 on 26-Oct-2018.
Last one week high and low of the scrip stood at Rs. 353.40 and Rs. 344.30 respectively. The current market cap of the company is Rs. 35749.09 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.34% and 7.87% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Betamethasone Dipropionate Cream USP (US RLD - DIPROLENE AF), 0.05%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. This medication is a strong corticosteroid and is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Betamethasone reduces the swelling, itching, and redness that can occur in these types of conditions.
The group also received a final approval for Amlodipine and Atorvastatin Tablets USP (US RLD - Caduet) in the strengths of 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10mg/80 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This combination product contains two active ingredients - amlodipine and atorvastatin. Amlodipine reduces blood pressure and the workload on the heart by relaxing the walls of the blood vessels. It is used to lower blood pressure and to treat angina (chest pain). Atorvastatin is used in combination with diet and exercise to treat high cholesterol. It works by blocking an enzyme that is needed to make cholesterol in the body.
The group now has 245 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
A Special Offer for a Special Season! Get Stock Cash Tips to start from 2 Days Free Trial Click Here- Stock Cash Tips "we provide secure, Smooth Deals You Can Trust"
0 comments
Note: only a member of this blog may post a comment.